Wanbury Q2 FY27 Results (NSE: WANBURY)
Signal: Steady quarter
The read
The operating inflection is visible in standalone Q2: revenue rose 10.5% QoQ to ₹18,290.97 lakh, EBITDA margin improved to 14.4% from approximately 10.5%, and PAT rose 266.4% to ₹1,188.23 lakh; however, first-time consolidation of Wanbury Skin Health reduced group PAT to ₹852.62 lakh because of its ₹335.60 lakh pre-operative loss.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹182.91 Cr | N/A | N/A |
| EBIT | ₹18.66 Cr | N/A | |
| Net profit | ₹8.53 Cr | N/A | |
| EPS | ₹2.44 | N/A | |
| EBIT margin | 10.2% |
P&L walk
Q2 consolidated revenue was ₹18,290.97 lakh, while PAT was ₹852.62 lakh after the newly consolidated subsidiary recorded a ₹335.60 lakh loss; no comparable consolidated prior-quarter or year-ago columns were presented.
Segments
Wanbury remains a single reported Pharmaceuticals segment, but the consolidated result was dragged by the newly included Wanbury Skin Health subsidiary, which had nil revenue and a ₹335.60 lakh net loss in Q2FY27.
Key positives
- Standalone revenue reached ₹18,290.97 lakh, up 10.5% QoQ from ₹16,558.35 lakh, despite the absence of a printed year-ago Q2 comparison.
- Standalone EBITDA margin improved to 14.4% from approximately 10.5% in Q1FY27, a sequential expansion of about 390bps, while derived EBITDA rose to ₹2,633.58 lakh from ₹1,736.98 lakh.
- Standalone PAT increased 266.4% QoQ to ₹1,188.23 lakh, supported by finance costs falling 21.0% QoQ to ₹629.96 lakh.
- H1 operating cash flow was ₹3,753.03 lakh versus H1 consolidated PAT of ₹1,176.87 lakh, providing a positive cash-conversion signal.
Key concerns
- The new Wanbury Skin Health subsidiary reported nil revenue and a ₹335.60 lakh loss in Q2FY27, reducing consolidated PAT to ₹852.62 lakh from standalone PAT of ₹1,188.23 lakh.
- Consolidated borrowings were ₹22,361.45 lakh against cash of ₹799.61 lakh, implying derived net debt of ₹21,561.84 lakh at 30 September 2026.
- The filing provides no consolidated year-ago or prior-quarter comparison because the subsidiary was incorporated during the period, limiting assessment of group-level growth momentum.
Research and educational content only. Not investment advice.